628 Results
Sort By:
Published on May 9, 2016
An international team of researchers has uncovered a multitude of new driver mutations in lung cancer cells that may be responsive to genomically targeted and to immune cell therapies. “We have identified several distinct recurrent mutations that are likely to be recognized by the immune system and therefore would be…
Published on April 15, 2016
The past several years have seen some exciting results for cancer immunotherapy. However, there remains a fundamental lack of understanding of immune system recognition in various cancers. Many large-scale sequencing efforts have added to our collective knowledge base, but too many of these studies have been deficient in comprehensive epidemiological…
Published on March 7, 2016
A blood test may be able to sound early warning bells that patients with advanced melanoma skin cancer are relapsing, according to a study (“Application of Sequencing, Liquid Biopsies and Patient-Derived Xenografts for Personalized Medicine in Melanoma”) published in Cancer Discovery. Scientists from the Cancer Research UK Manchester Institute studied…
Published on March 4, 2016
For all its genetic diversity, a tumor may yet display some common elements, antigens that reflect the tumor’s early mutational history. If these common elements could be identified, they could be used to target practically all of the tumor’s cells for destruction, and not just tumor cells that happen to…
Published on January 11, 2016
Thermo Fisher Scientific plans to buy Affymetrix for $1.3 billion, in a deal the buyer said will strengthen its position in bioscience research tools and genetic analysis. The deal, announced Friday after the close of financial markets, expands Thermo Fisher’s offerings with Affymetrix’s technologies, designed to enable parallel and multiplex…
Published on January 5, 2016
Virtual tumors—computer simulations that incorporate a patient’s genomic information—can help personalize cancer care. They have already been used to predict patient responses to drug treatments. In particular, virtual tumors have identified which patients are likely to respond to checkpoint inhibitors, drugs meant to prevent cancers from overriding host immune checkpoints.…
Published on January 5, 2016
Tumors aren’t mere blobs of cancer cells. They are complex structures. Besides cancer cells, they contain immune cells, fibroblasts, and cells that constitute supporting blood vessels. These noncancerous cells, it is known, play an important role in cancer biology. What is not known, however, is how these cells influence genomic…
Published on December 10, 2015
Berkeley Lights, which focuses on opto-nanofluidic biosystems, signed an agreement with the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai that provides early access to Berkeley Lights’ instrumentation incorporating its OptoSelect™ light technology for single-cell annotation and genomics in research applications. Scientists at Mount Sinai say are using…
Published on September 30, 2015
Generex Biotechnology has agreed to acquire for $15 million a 51% majority equity interest in Hema Diagnostic Systems (HDS), but could reap up to $50 million in royalties from gross sales of HDS tests, the companies said today. While saying it entered into a non-binding letter of intent for the…